Literature DB >> 1676922

Torsades de pointes complicating treatment with terodiline.

A A McLeod, S Thorogood, S Barnett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1676922      PMCID： PMC1670155          DOI： 10.1136/bmj.302.6790.1469-c

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  2 in total

1.  Ventricular arrhythmias caused by prenylamine.

Authors:  R Puritz; M A Henderson; S N Baker; D A Chamberlain
Journal:  Br Med J       Date:  1977-09-03

Review 2.  Terodiline. A review of its pharmacological properties, and therapeutic use in the treatment of urinary incontinence.

Authors:  H D Langtry; D McTavish
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546
  2 in total
  11 in total

1.  Terodiline and torsades de pointes.

Authors: 
Journal:  BMJ       Date:  1991-08-31

2.  QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman.

Authors:  Hiroshi Asajima; Yohei Sekiguchi; Shoji Matsushima; Naotaka Saito; Takahiko Saito
Journal:  Br J Clin Pharmacol       Date:  2008-12       Impact factor: 4.335

3.  Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K(+) currents and action potentials.

Authors:  S E Jones; L M Shuba; P Zhabyeyev; J R McCullough; T F McDonald
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 4.  Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.

Authors:  Galia Jackobson; Narin Nard Carmel; Dor Lotan; Anjelika Kremer; Dan Justo
Journal:  Z Gerontol Geriatr       Date:  2016-11-22       Impact factor: 1.281

5.  Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval.

Authors:  D A Stewart; J Taylor; S Ghosh; G J Macphee; I Abdullah; J M McLenachan; D J Stott
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

6.  Block and modified gating of cardiac calcium channel currents by terodiline.

Authors:  T Ogura; S Jones; L M Shuba; J R McCullough; T F McDonald
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

7.  Electrophysiological profile of propiverine--relationship to cardiac risk.

Authors:  Torsten Christ; Erich Wettwer; Melinda Wuest; Manfred Braeter; Frank Donath; Pascal Champeroux; Serge Richard; Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-19       Impact factor: 3.000

Review 8.  Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence.

Authors:  S H Thomas; P D Higham; K Hartigan-Go; F Kamali; P Wood; R W Campbell; G A Ford
Journal:  Br Heart J       Date:  1995-07

Review 10.  The Q-T interval and antimuscarinic drugs.

Authors:  Roger Dmochowski; David R Staskin
Journal:  Curr Urol Rep       Date:  2005-11       Impact factor: 2.862
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.